Eton Pharmaceuticals Files 8-K
Ticker: ETON · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1710340
Sentiment: neutral
Topics: 8-K, SEC Filing, Disclosure
TL;DR
Eton Pharma filed an 8-K, check for updates.
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K on December 3, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text.
Why It Matters
This filing indicates Eton Pharmaceuticals is providing updates or disclosures to the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The filing is a standard disclosure form without immediate negative or positive financial implications presented in the text.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- December 3, 2024 (date) — Date of Report
- 21925 W. Field Parkway, Suite 235 (address) — Principal executive offices
- Deer Park, Illinois (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing for Eton Pharmaceuticals?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 3, 2024.
What is Eton Pharmaceuticals' exact name as specified in its charter?
Eton Pharmaceuticals, Inc.
In which state was Eton Pharmaceuticals incorporated?
Delaware.
What is the principal executive office address for Eton Pharmaceuticals?
21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208.
What is the telephone number for Eton Pharmaceuticals?
The registrant's telephone number is (847) 787-7361.
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-12-03 07:00:09
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20241127_8k.htm (8-K) — 27KB
- ex_752772.htm (EX-99.1) — 11KB
- 0001437749-24-036504.txt ( ) — 172KB
- eton-20241203.xsd (EX-101.SCH) — 3KB
- eton-20241203_def.xml (EX-101.DEF) — 11KB
- eton-20241203_lab.xml (EX-101.LAB) — 15KB
- eton-20241203_pre.xml (EX-101.PRE) — 11KB
- eton20241127_8k_htm.xml (XML) — 3KB
01: Other Events
Item 8.01: Other Events On December 3, 2024, Eton Pharmaceuticals, Inc. (the "Company") announced the appointment of Ipek Erdogan-Trinkaus, MBA, as Chief Commercial Officer (CCO), effective immediately. Prior to joining Eton, Ms. Erdogan-Trinkaus served as Chief Commercial Officer of a leading plant-based food and beverage brand, milkadamia TM , from initial launch phase of building the brand to implementing a long-term growth strategy to drive its evolution into a mature business. She was previously with Tolmar Pharmaceuticals, Inc., where she held a variety of leadership roles of increasing responsibility, including VP of Commercial Strategy and Global Marketing, leading up to her assignment to General Manager of the Pediatric Endocrinology business unit. She has also held various commercial leadership roles at Ameda, Inc., Mead Johnson Nutrition, and Abbott Nutrition. Ms. Erdogan-Trinkaus received her Bachelor of Science in Business Administration from Middle East Technical University, the top-ranked university in Turkey, and her MBA from The Ohio State University's Fisher College of Business. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. 2
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 99.1 Press Release dated December 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 3, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4